Doctor-prescribed, fully online, starting at $179 per month. No insurance required.
Start Your Free EvaluationGLP-1 receptor agonists mimic natural incretin hormones that regulate blood sugar and appetite. By restoring this signaling pathway, medication helps your body recognize fullness sooner and maintain stable energy levels.
Clinical trials show average daily caloric intake drops 20-35% without conscious restriction. Medication slows gastric emptying and targets brain centers responsible for cravings, making portion control feel effortless.
Dieting alone often lowers resting metabolic rate, leading to plateaus. GLP-1 therapy preserves lean mass while selectively reducing fat, allowing sustainable weight loss of 1–2 pounds per week for 12+ months.
Once-weekly injection that reduces hunger and improves glycemic control. FDA-approved for chronic weight management.
$179 / month
Average 15% body-weight reduction at 68 weeks.
Learn MoreDual GIP/GLP-1 receptor agonist offering enhanced fat-loss and glucose-lowering effects. Once-weekly injection.
$379 / month
Average 20% body-weight reduction at 72 weeks.
Learn More histories.Fill out a secure medical questionnaire and upload recent labs if available. The process takes under 10 minutes.
A licensed clinician reviews your history, confirms eligibility, and prescribes the appropriate medication during a virtual visit.
Your medication ships in temperature-controlled packaging. Ongoing support, dosage adjustments, and refills are managed through your patient portal.
Candidates generally meet the following criteria. Final approval is determined by a licensed medical provider.
Review efficacy, dosing, and side-by-side costs to choose the best fit for your goals.
Compare Semaglutide vs TirzepatideMedical weight loss combines prescription medication with clinician oversight to address biological drivers of obesity. Unlike commercial diets, the program targets hormone pathways that control hunger and fat storage, producing clinically significant weight reduction without invasive procedures.
Adults aged 18-75 with a BMI of 27 or above and at least one weight-related condition—such as hypertension, type 2 diabetes, or dyslipidemia—are potential candidates. Individuals with BMI ≥ 30 may qualify even without additional conditions. Contraindicated conditions include medullary thyroid carcinoma, MEN2, pancreatitis, or pregnancy.
Semaglutide plans start at $179 per month; Tirzepatide at $379 per month. Pricing includes provider consultations, medication, supplies, and ongoing messaging support. Labs and shipping are additional. No insurance is required, but HSA/FSA funds are accepted.
Novolene operates on a transparent cash-pay model to avoid prior-authorization delays and coverage gaps. Patients may submit itemized receipts to their insurer for potential out-of-network reimbursement; however, we cannot guarantee payment.
Most patients notice reduced appetite within 48 hours of the first dose. Steady weight loss of 1–2 lb per week typically begins by week 4 once the therapeutic dose is reached. Maximum results accrue over 9–15 months alongside modest lifestyle adjustments.
GLP-1 receptor agonists have been prescribed for type 2 diabetes since 2005 and for obesity since 2021, accumulating over 15 years of post-market surveillance. Common side effects are mild gastrointestinal symptoms that resolve spontaneously. Serious events are rare and thoroughly reviewed during screening and follow-up visits.
Complete a free evaluation to see if prescription GLP-1 therapy is right for you. No commitment until you approve treatment.
Start Your Free Evaluation